Glaucoma Screening
eBook - PDF

Glaucoma Screening

  1. 164 pages
  2. English
  3. PDF
  4. Available on iOS & Android
eBook - PDF

Glaucoma Screening

Book details
Table of contents
Citations

Frequently asked questions

Simply head over to the account section in settings and click on “Cancel Subscription” - it’s as simple as that. After you cancel, your membership will stay active for the remainder of the time you’ve paid for. Learn more here.
At the moment all of our mobile-responsive ePub books are available to download via the app. Most of our PDFs are also available to download and we're working on making the final remaining ones downloadable now. Learn more here.
Both plans give you full access to the library and all of Perlego’s features. The only differences are the price and subscription period: With the annual plan you’ll save around 30% compared to 12 months on the monthly plan.
We are an online textbook subscription service, where you can get access to an entire online library for less than the price of a single book per month. With over 1 million books across 1000+ topics, we’ve got you covered! Learn more here.
Look out for the read-aloud symbol on your next book to see if you can listen to it. The read-aloud tool reads text aloud for you, highlighting the text as it is being read. You can pause it, speed it up and slow it down. Learn more here.
Yes, you can access Glaucoma Screening by R.N. Weinreb in PDF and/or ePUB format, as well as other popular books in Medicine & Opthalmology & Optometry. We have over one million books available in our catalogue for you to explore.

Information

Year
2008
ISBN
9789062992188

Table of contents

  1. FACULTY
  2. CONTENTS
  3. PREFACE
  4. WELCOME
  5. SCREENING FOR OPEN-ANGLE GLAUCOMA (OAG)
  6. IS OAG AN IMPORTANT HEALTH
  7. IS THERE AN ACCEPTED AND EFFECTIVE TREATMENT FOR PATIENTS WITH THE DISEASE THAT IS MORE EFFECTIVE AT PREVENTING MORBIDITY WHEN INITIATED IN THE EARLY, ASYMPTOMATIC STAGE THAN WHEN BEGUN IN THE LATER, SYMPTOMATIC STAGES?
  8. ARE FACILITIES FOR DIAGNOSIS AND TREATMENT AVAILABLE?
  9. IS THERE AN APPROPRIATE, ACCEPTABLE, AND REASONABLY ACCURATE SCREENING TEST?
  10. IS THE NATURAL HISTORY OF THE CONDITION, INCLUDING DEVELOPMENT FROM LATENT TO MANIFEST DISEASE, ADEQUATELY UNDERSTOOD?
  11. IS THE COST OF CASE FINDING (INCLUDING DIAGNOSIS AND TREATMENT OF PATIENTS DIAGNOSED) ECONOMICALLY BALANCED IN RELATION TO POSSIBLE EXPENDITURE ON MEDICAL CARE AS A WHOLE?
  12. SCREENING FOR PRIMARY ANGLE CLOSURE AND PRIMARY ANGLE-CLOSURE GLAUCOMA
  13. ARE ANGLE CLOSURE (AC) AND ANGLE-CLOSURE GLAUCOMA (ACG) IMPORTANT HEALTH PROBLEMS?
  14. IS THERE AN ACCEPTED AND EFFECTIVE TREATMENT FOR PATIENTS WITH ANGLE-CLOSURE GLAUCOMA (ACG) THAT IS MORE EFFECTIVE AT PREVENTING MORBIDITY WHEN INITIATED IN THE EARLY, ASYMPTOMATIC STAGE THAN WHEN BEGUN IN THE LATER, SYMPTOMATIC STAGES?
  15. ARE FACILITIES FOR DIAGNOSIS AND TREATMENT AVAILABLE?
  16. IS THERE AN APPROPRIATE, ACCEPTABLE, AND REASONABLY ACCURATE SCREENING TEST?
  17. IS THE NATURAL HISTORY OF THE CONDITION, INCLUDING DEVELOPMENT FROM LATENT TO MANIFEST DISEASE, ADEQUATELY UNDERSTOOD?
  18. IS THE COST OF CASE FINDING (INCLUDING DIAGNOSIS AND TREATMENT OF PATIENTS DIAGNOSED) ECONOMICALLY BALANCED IN RELATION TO POSSIBLE EXPENDITURE ON MEDICAL CARE AS A WHOLE?
  19. INDEX OF AUTHORS
  20. SUMMARY CONSENSUS POINTS